This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebedeva, I. V. Articles by Fisher, P. B. Search for Related Content PubMed PubMed Citation Articles by Lebedeva, I. V. Articles by Fisher, P. B.

Melanoma Differentiation Associated Gene-7, mda-7/Interleukin-24, Induces Apoptosis in Prostate Cancer Cells by Promoting Mitochondrial Dysfunction and Inducing Reactive Oxygen Species

¹ Departments of Pathology,
² Urology, and
³ Neurosurgery, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York;
⁴ Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia;
⁵ Department of Medicine, Mount Sinai Medical Center, New York, New York; and
⁶ The Burnham Institute, La Jolla, California

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Mda-7/IL-24 (Ad.mda-7) is a novel cytokine gene belonging to the interleukin (IL) 10 gene superfamily. Adenoviral-mediated delivery of mda-7/IL-24 causes growth suppression and apoptosis in a wide spectrum of cancer cells, including prostate, without harming normal cells. We now demonstrate that Ad.mda-7 selectively induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and reactive oxygen species (ROS) production. Antioxidants (N-acetyl-L-cysteine and Tiron) and inhibitors of mitochondrial permeability transition (cyclosporine A and bongkrekic acid) inhibit Ad.mda-7-induced mitochondrial dysfunction and apoptosis. Conversely, agents augmenting ROS production (arsenic trioxide, NSC656240, and PK11195) facilitate Ad.mda-7-induced apoptosis. Ectopic expression of Bcl-2 and Bcl-x_L inhibits mitochondrial changes, ROS production, and apoptosis providing additional support for an association between mitochondrial dysfunction and Ad.mda-7 action. These studies present definitive evidence that changes in mitochondrial function and ROS production are key components associated with selective killing of prostate cancer cells by mda-7/IL-24.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Subtraction hybridization and microarray analyses are defining the spectrum of gene expression changes occurring as a consequence of induction of irreversible growth arrest and terminal differentiation in human melanoma cells (1 , 2) . Application of the subtraction hybridization approach to terminal differentiation in human melanoma cells resulted in the cloning of mda-7⁷ (3) . Expression of mda-7 inversely correlates with tumorigenic progression from melanocyte to malignant melanoma suggesting a putative function as an inhibitor of melanoma progression (3 , 4) . On the basis of its structure, cytokine-like properties, and proposed mode of action, mda-7 has now been classified as IL-24 (5 , 6) . Initial studies focused on the growth inhibitory properties of this molecule, resulting in the provocative observation that mda-7/IL-24 selectively suppresses the growth of a broad spectrum of tumor cells, without affecting growth of normal cells (3 , 7) . When introduced into tumor cells by adenovirus transduction, Ad.mda-7 induces apoptosis in multiple cancer cell types but not in normal cells (8 , 9) . On the basis of the apparent selectivity of mda-7/IL-24 toward cancer cells in vitro and animal studies confirming antitumor properties in vivo, Ad.mda-7 was evaluated recently in a Phase I/II clinical trial in patients with advanced carcinomas (10) . These studies document that Ad.mda-7 (INGN 241) is safe, and a single intratumoral injection can result in >70% tumor apoptosis with a concomitant inhibition in disease progression.

On the basis of the potential utility of mda-7/IL-24 for the gene-based therapy of multiple cancers, understanding the mechanism by which this gene selectively induces apoptosis in cancer cells will be of immense value. Studies initially performed in the context of human breast carcinoma cells documented that Ad.mda-7 up-regulates expression of the proapoptotic protein Bax and decreases expression of the antiapoptotic protein Bcl-2, thereby shifting the balance from survival to death (8) . Moreover, both overexpression of Bcl-2 or the adenovirus type 5 E1B proteins were able to protect breast cancer cells from loss of survival after infection with Ad.mda-7 suggesting that changes in the levels of Bcl-2-family proteins and mitochondrial function are relevant to mda-7/IL-24 action (8) . Studies in additional model systems, including lung, pancreatic and prostate carcinomas, melanomas, and malignant gliomas provide additional support for a functional relationship between changes in the ratio of proapoptotic proteins, Bax and/or Bak, to antiapoptotic proteins, such as Bcl-2 and/or Bcl-x_L, in Ad.mda-7-induced apoptosis (5 , 11) . In addition, recent studies demonstrate that overexpression of Bcl-2 and Bcl-x_L can differentially protect specific prostate cancer cell lines from Ad.mda-7-induced apoptosis (12) . Although these studies provide support for a role of mitochondria in Ad.mda-7-induced apoptosis, definitive evidence for such an involvement is lacking. On the basis of these considerations, we have presently investigated the relationship between mitochondrial function and cellular redox status, and resistance or sensitivity to Ad.mda-7-induced apoptosis in normal and tumor-derived human prostate cells. These studies document the importance of dysregulation of mitochondrial functions and redox changes as cellular pathways specifically perturbed by Ad.mda-7, which culminate in the selective induction of apoptosis in prostate cancer cells.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Cell Lines and Virus Infection Protocol.
Human DU-145, PC-3, and LNCaP prostate carcinoma cells were obtained from the American Type Culture Collection and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1% MEM sodium pyruvate, and nonessential amino acids. P69, an SV40-immortalized human prostate epithelial cell line was provided by Dr. Joy Ware (Virginia Commonwealth University, Richmond, VA) and grown under serum-free conditions as described previously (13) . Bcl-2 and Bcl-x_L stable overexpressing clones of each prostate cancer cell line were generated and cultured as described (12) . The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously (8) and plaque purified by standard procedures. Cells were infected with 100 plaque forming units/cell of Ad.mda-7 or Ad.vec(30 plaque forming units/cell for LNCaP cells) and analyzed as described.

MTT Viability Assays.
Cell viability was assessed by MTT assays as described (12) . Briefly, cells were seeded in 96-well tissue culture plates (1.5 x 10³ cells/well) and treated with various agents. At the indicated times, medium was removed, and fresh medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated at 37°C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well and mixed thoroughly. The absorbance from the plates was read on a Bio-Rad Microplate Reader Model 550 at 595 nm.

Annexin V Binding Assays.
Cells were trypsinized, washed once with complete medium, and stained with FITC-labeled Annexin-V (kit from Oncogene Research Products, Boston, MA) according to the manufacturer’s instructions. Flow cytometry was performed immediately after staining.

Assessment of Mitochondrial _m and ROS Production.
Changes in mitochondrial transmembrane potential _m were determined by staining cells in 20 nM of DiOC₆(3) in PBS for 30 min at 37°C in the dark. The dye accumulates in actively respiring mitochondria depending on _m (14) . Controls were performed in the presence of 50 µM mitochondrial uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (Sigma). To determine ROS production, cells were stained with 2.5 µM HE or 5 µM DCFH-DA in PBS for 30 min at 37°C in the dark (15) . Immediately after staining, cells were analyzed by flow cytometry (FACSscan; Becton-Dickinson, Mountain View, CA), and data were analyzed using CellQuest software, version 3.1 (Becton Dickinson). For inhibition experiments, NAC, CsA, BA (all from Sigma) or z-VAD.fmk (Calbiochem, La Jolla, CA) were added 2 h before infection with Ad.mda-7. In all of the cases, cells were gated to exclude cell debris.

Statistical Analysis.
All of the experiments were performed at least three times. Results are expressed as mean ± SE Statistical comparisons were made using an unpaired two-tailed Student’s t test. A P < 0.05 was considered significant.

	Results and Discussion

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Ad.mda-7 Induces ROS and Apoptosis Selectively in Prostate Cancer Cells.
Ad.mda-7 infection inhibits proliferation and induces apoptosis in diverse prostate cancer cell lines but not in normal human prostate epithelial cells (12) . Moreover, overexpression of antiapoptotic members of the Bcl-2-family differentially protects prostate carcinoma cells from Ad.mda-7-induced apoptosis. In the present study, we used these model systems to determine whether Ad.mda-7 regulates the levels of intracellular ROS and whether a rise in ROS is necessary for Ad.mda-7-mediated apoptosis.

ROS (including singlet oxygen and hydrogen peroxide, as well as free radicals such as superoxide anion and hydroxyl radicals) regulate apoptosis and proliferation in response to a variety of stimuli, including tumor necrosis factor-, UV and -irradiation, and anthracyclines (16) . To determine whether ROS production contributes to apoptosis induction by Ad.mda-7 in prostate cancer cells, normal immortal prostate epithelial cells (P69; Ref. 13 ) and prostate carcinoma cells were infected with Ad.vec or Ad.mda-7, and the effect of antioxidants (NAC and Tiron) on Ad.mda-7-induced cell death was evaluated by MTT assays. In the presence of noncytotoxic doses of a general antioxidant, NAC (5 mM), or a free radical and hydrogen peroxide scavenger, Tiron (1 mM), the cell death promoting activity of Ad.mda-7 was abrogated in all three of the prostate carcinoma cell lines (Fig. 1A) . This inhibitory effect of antioxidant treatment was not associated with altered MDA-7 cellular or secreted protein levels (data not shown). To explore the relationship between ROS and Ad.mda-7-induced apoptosis additional experiments were performed with As₂O₃ and NSC656240 (a dithiophene), two agents that can promote ROS production and apoptosis in cancer cells (Refs. 17 , 18 ; Fig. 1B ).⁸ Cotreatment of Ad.mda-7-infected prostate cancer cells with noncytotoxic doses of As₂O₃ (0.5 µM) or NSC656240 (400 nM) potentiated cell death in all three of the prostate carcinoma cell lines but not in normal immortal P69 prostate epithelial cells (Fig. 1B) . These observations suggest that free radicals may contribute to Ad.mda-7 induction of apoptosis in prostate carcinoma cells.

View larger version (45K): [in this window] [in a new window]   Fig. 1. ROS induction correlates with Ad.mda-7-induced cell death in prostate cancer cells. A, Ad.mda-7-induced cell death is inhibited by antioxidants. Cells were seeded in 96-well plates, pretreated with NAC (5 mM) or Tiron (1 mM) for 2 h, and infected with Ad.mda-7. Forty-eight h later, viability was assessed by MTT assay. B, ROS-producing substances enhance Ad.mda-7-induced cell death. Cells were seeded in 96-well plates, infected with Ad.mda-7, and treated with As2O3 (0.5 µM) or NSC656240 (400 nM). Forty-eight h later, viability was assessed by MTT assay. C, treatment of prostate carcinoma cells with Ad.mda-7 induces ROS generation that is blocked by NAC and is enhanced by NSC656240 and As2O3 (ARS). After treatment, cells were stained using DCFH-DA as described in "Materials and Methods" and analyzed using flow cytometry. D, antioxidant treatment blocks or significantly inhibits apoptosis induced by Ad.mda-7 in prostate cancer cells, whereas NSC656240 and As2O3 (ARS) treatment increases apoptosis induced by Ad.mda-7. After treatment, cells were washed and stained with annexin V-FITC conjugate. Late apoptotic and necrotic cells were excluded using propidium iodide staining. Results are the mean of three independent experiments performed with triplicate samples; bars, ±SE.

Flow cytometry analysis of cellular fluorescence revealed that Ad.mda-7 infection produced a 3–5-fold increase in ROS production in prostate carcinoma cells but not in normal P69 cells (Fig. 1C) . The largest ROS induction effect was apparent in LNCaP cells followed by DU-145 cells with the smallest changes occurring in PC-3 cells. Similarly, when treated with NSC656240 or As₂O₃, ROS levels increased in all of the prostate carcinoma cells with the greatest level of induction being apparent in LNCaP cells (Fig. 1C) . Treatment with a noncytotoxic dose of NAC suppressed Ad.mda-7-induced ROS generation, and also inhibited As₂O₃ and NSC656240 stimulated ROS generation in prostate cancer cells (Fig. 1 C; data not shown). The increase in ROS production coincided with apoptosis induction in the prostate cancer cell lines, as confirmed by Annexin V binding (Fig. 1D) . As observed for ROS induction, pretreatment with nontoxic doses of NAC prevented Ad.mda-7-induced apoptosis. Moreover, a combination treatment with Ad.mda-7 plus As₂O₃ or NSC656240 increased apoptosis to variable extents in the three prostate cancer cell lines, without inducing apoptosis in normal P69 cells (Fig. 1D) .

Ad.mda-7 Temporally and Selectively Induces ROS Production and _m Reduction in Prostate Carcinoma Cells.
Because ROS may play a dual role in apoptosis, either being a modulator of mitochondrial membrane potential loss or a consequence of this change, depending on the death stimuli (14 , 19) , we determined the time course of mitochondrial changes (ROS, _m, and membrane apoptotic changes (Annexin V binding) after Ad.vecor Ad.mda-7 infection (Fig. 2) . Cells were infected with Ad.vecor Ad.mda-7 at the indicated multiplicity of infection, collected at different times up to 60 h, and stained for ROS production with DCFH-DA and with the cationic mitochondrial dye DiOC₆(3) , which accumulates in active mitochondria, to determine changes in _m (14) . In parallel, annexin V binding assays were performed as described in "Materials and Methods."

View larger version (42K): [in this window] [in a new window]   Fig. 2. Kinetics of mitochondrial alteration, ROS generation, and plasma membrane changes induced by Ad.mda-7 treatment of prostate cancer and immortalized normal cells. Cells were infected with Ad.vec or Ad.mda-7, and analyzed using flow cytometry at indicated times. Changes in the mitochondrial transmembrane potential m () were measured with DiOC6(3), and ROS generation was measured using DCFH-DA (, hydrogen peroxide and NO). The percentage of apoptotic cells (, right Y-axis) was measured using simultaneous staining with annexin V-FITC conjugate and propidium iodide. Because the data for Ad.vec-infected cells were not significantly different from the data for control (untreated cells), Ad.mda-7-related data are presented in this figure. Results are the average of three independent experiments that varied by 10%.

It is worth noting that in all of the prostate cancer cell lines, a correlation was observed between mitochondrial changes and MDA-7 protein expression. Mitochondrial changes in Ad.mda-7-infected prostate cancer cells first became apparent when MDA-7 protein was initially detected by immunoblotting (data not shown). In a previous study, we demonstrated that MDA-7 protein first appeared by 6–9 h after Ad.mda-7 infection of prostate cancer cells (12) . However, despite similar kinetic changes in MDA-7 protein expression in Ad.mda-7-infected normal prostate epithelial cells, no decline in survival, mitochondrial functions, or induction of apoptosis were evident (Fig. 2 ; Ref. 12 ).

Ad.mda-7 Infection Modulates MPT in Prostate Cancer Cells.
Because ROS production and the decline in _m were directly associated with apoptosis or reduced cell survival in prostate carcinoma cells infected with Ad.mda-7 (Fig. 2) , the role of MPT in Ad.mda-7-induced apoptosis was investigated. MPT is characterized by the opening of mitochondrial megachannels to allow solutes and water to enter the mitochondria (20) . MPT can be triggered by ROS or other agents resulting in a decrease in _m, followed by depletion of ATP or activation of caspases/endonucleases (reviewed in Ref. 19 ). This process is controlled by a multiprotein complex found in the inner and outer membranes of the mitochondria known as the PTP (20) . The PTP consists of voltage-dependent anion channel/porin, adenosine nucleotide translocator, cyclophilin D, the complex forming the PBzRs, and other proteins (20) . Upon PTP opening, the mitochondria lose their _m across the inner membrane culminating in apoptosis accompanied by an immediate shutdown of mitochondrial biogenesis. Another consequence of _m disruption is the uncoupling of oxidative phosphorylation (21) and the generation of superoxide anion on the uncoupled respiratory chain resulting in additional damage to proteins and membranes (14) .

CsA and BA specifically bind to different components of the PTP complex (cyclophilin D and adenosine nucleotide translocator, respectively), thereby preventing mitochondrial membrane permeabilization and apoptosis in a wide variety of cell types (14 , 22, 23, 24) . On the other hand, the PBzR agonist (PK11195) can potentiate the induction of MPT (25) . On the basis of these considerations, prostate cancer cells and normal P69 cells were pretreated with nontoxic doses of CsA (200 nM), BA (50 µM), or PK11195 (50 µM) for 2 h postinfection with Ad.vec or Ad.mda-7, and cellular viability and early (cytoplasmic) apoptosis were accessed 18 h (LNCaP cells) and 24 h (DU-145, PC-3, and P69 cells) after infection. Pretreatment with CsA or BA prevented cell death (Fig. 3A) and annexin V exposure in Ad.mda-7-infected prostate cancer cells (Fig. 3C) . Analysis of mitochondrial changes [DiOC₆(3) retention] and ROS production (DCFH-DA staining) confirmed that CsA and BA abrogated the decline in _m (Fig. 3B) . In a recent study using two lung cancer cell lines, H1299 and A549, Ad.mda-7 induced changes in _m only in A549 cells and CsA did not prevent Ad.mda-7-induced cell death in either of these cell types or alter _m in A549 cells (26) . The reason for these differences among prostate carcinoma and lung carcinoma cell lines is not currently known but could reflect inherent differences in the mode of action of mda-7/IL-24 in these two tumor cell types or simply differences in experimental protocols, i.e., the dose of CsA used, the temporal kinetics of changes investigated, and/or a different protocol to measure _m (15) . PK11195 increased mitochondrial depolarization, annexin V staining, and enhanced Ad.mda-7-induced killing in DU-145, PC-3, and LNCaP, without inducing any of these changes in P69 cells (Fig. 3, A–C) . The ability of CsA and BA to inhibit _m decline, ROS production, and apoptosis, and the ability of a PBzR agonist to promote these changes highlights the importance of mitochondria and MPT as arbiters of Ad.mda-7-induced death in prostate carcinoma cells (Fig. 4C) .

View larger version (33K): [in this window] [in a new window]   Fig. 3. MPT is an early event in Ad.mda-7-induced cell death and apoptosis preceding caspase activation. Prostate cancer and normal immortalized P69 cells were pretreated with inhibitors of MPT CsA (100 nM) or BA (50 µM), with the enhancer of MPT PK11195 (50 µM), or with the pan-caspase inhibitor z-VAD.fmk (50 µM) for 2 h after infection with Ad.vec or Ad.mda-7. Cellular viability was assessed by MTT assay 48 h after infection (A). Mitochondrial membrane potential [DiOC6(3) staining; B] and apoptotic changes (annexin V staining; C) were assessed 18 h (LNCaP cells) and 24 h (DU-145, PC-3, and P69 cells) after infection.

View larger version (41K): [in this window] [in a new window]   Fig. 4. Bcl-2 and Bcl-xL overexpression differentially protects prostate cancer cells from Ad.mda-7-induced cell death and apoptosis by blocking MPT and subsequent ROS generation, and a model for Ad.mda-7-induced changes in mitochondria culminating in apoptosis. Prostate cancer cells stably transfected with Bcl-2, Bcl-xL, or empty vector (neo) were infected with Ad.vec or Ad.mda-7 as described and mitochondrial membrane potential [DiOC6(3) staining (A)] and ROS production (DCF-DA staining; B) were assessed 18 h (LNCaP cells) and 24 h (DU-145, PC-3, and P69 cells) after infection. C, proposed model for Ad.mda-7-induced apoptosis in prostate cancer cell lines. After Ad.mda-7 infection, MDA-7 protein directly or indirectly affects mitochondria, causing alterations in mitochondrial function (decrease in m and MPT) and ROS production. The reduction in m and MPT are caspase-independent, because they are not inhibited by the general caspase inhibitor z-VAD.fmk. Moreover, MPT can be blocked by inhibitors of MPT, such as CsA and BA, and can be promoted by activators of MPT, such as PK11195, a PBzR agonist. ROS inhibitors (NAC and Tiron) block Ad.mda-7-induced apoptosis, whereas ROS producers (As2O3 and NSC656240) enhance apoptosis only in the context of prostate cancer cells.

Bcl-2 and Bcl-x_L Differentially Protect Prostate Cancer Cells from ROS Induction and Decreased _m After Infection with Ad.mda-7.
We demonstrated previously that overexpression of Bcl-2 and Bcl-x_L can differentially protect prostate carcinoma cells from apoptosis induced by Ad.mda-7 (12) . These bcl-2-family members have also been found to protect diverse cell types from ROS-dependent (29 , 30) and ROS-independent (31) apoptosis. Extensive research on the mechanism of inhibition of apoptosis by Bcl-2 has focused on its interaction with and regulation of mitochondrial function, particularly the mitochondrial permeability pore (32 , 33) . However, the localization of Bcl-2 to intracellular sites of oxygen-free radical generation, including the cytoplasmic face of the mitochondrial outer membrane, endoplasmic reticulum, and nuclear membranes predict that Bcl-2 may exhibit antioxidant properties (30) . Furthermore, Bcl-2 knockout mice express a phenotype consistent with that of mice exposed to chronic oxidative stress (polycystic kidney disease and follicular hypopigmentation; Ref. 34 ).

In the present study, we examined the effect of overexpression of the antiapoptotic Bcl-2-family members on generation of ROS and changes in _m during Ad.mda-7-induced apoptosis. To examine the relationship between Bcl-2-family members, and changes in mitochondrial function and ROS we used a series of well-characterized prostate cancer cell clones displaying stable overexpression of Bcl-2 or Bcl-x_L (12) . In DU-145 and PC-3 cells overexpression of Bcl-x_L and not Bcl-2 prevented Ad.mda-7-induced apoptosis, whereas in LNCaP cells overexpression of Bcl-2 and not Bcl-x_L was protective (12) . As shown on Fig. 4 A, overexpression of Bcl-x_L completely abrogated the decline in _m in DU-145 and PC-3 cells after Ad.mda-7 infection, without preventing this change in LNCaP cells. In contrast, Bcl-2 overexpression, but not Bcl-x_L overexpression, prevented the reduction in _m in LNCaP cells on Ad.mda-7 infection. Similarly, Bcl-x_L, but not Bcl-2, protected DU-145 and PC-3 cells from Ad.mda-7-induced ROS induction, whereas Bcl-2, but not Bcl-x_L, protected LNCaP cells from this biochemical change (Fig. 4B) . These studies provide additional evidence that induction of apoptosis in prostate cancer cells by Ad.mda-7 is linked to changes in mitochondrial function (reduction in _m) and ROS production.

Concluding Remarks.
It is now firmly established that mda-7/IL-24 can induce apoptosis in a selective manner in a broad spectrum of cancer cells (7 , 8 , 11 , 12 , 35 , 36) . Although progress has been made in defining the signaling and biochemical events involved in mda-7/IL-24-induced apoptosis in cancer cells (5 , 36) , the precise mechanism underlying the cancer specificity of mda-7/IL-24 and the cellular targets of mda-7/IL-24 action remain essentially unknown. In the case of prostate, Ad.mda-7 induces apoptosis in carcinomas but not in normal prostate epithelial cells (12) . In contrast, overexpression of specific antiapoptotic members of the Bcl-2-family, Bcl-2 and Bcl-x_L, differentially protects prostate cancer cells from apoptosis (12) . On the basis of our present studies, a hypothetical model of Ad.mda-7-induced apoptosis in prostate cancer cells can be constructed (Fig. 4C) . In this model, Ad.mda-7 infection of prostate carcinoma cells, but not normal prostate epithelial cells, results in biochemical changes specifically in these tumor cells that result in mitochondrial dysfunction and ROS induction. Ad.mda-7 infection leads to the loss of _m and a burst of ROS, before the visualization of the apoptotic events such as phosphatidylserine exposure (as monitored by annexin V staining). In the apoptotic process, Ad.mda-7 induces mitochondrial depolarization, which is associated with MPT followed by ROS production. This apoptotic process is inhibited by simultaneous treatment with ROS inhibitors, NAC and Tiron, and potentiated by simultaneous treatment with ROS inducers, As₂O₃, NSC656240, and the PBzR agonist PK11195. The ability of Ad.mda-7 to induce a loss in _m, enhance ROS production, and trigger apoptosis is inhibited in specific prostate cancer cells by forced overexpression of antiapoptotic members of the Bcl-2 gene family, Bcl-2 or Bcl-x_L. These studies document a relationship between mitochondrial dysfunction and ROS induction and sensitivity to apoptosis induction by mda-7/IL-24 in prostate cancer cells. Our results also suggest that the ability of Ad.mda-7 to selectively kill prostate cancer cells can be augmented by agents that enhance mitochondrial dysfunction and induce ROS production. This finding may suggest strategies for enhancing the cancer-specific, apoptosis-inducing properties of this novel cytokine for translational applications in cancer therapy (36) .

	FOOTNOTES

 
Grant support: NIH Grants CA97318 and CA98712, DAMD-02-1-0041, the Samuel Waxman Cancer Research Foundation, and the Chernow Endowment (P. B. F.); NIH grants DK52825, CA88906, and CA72955. (P. D.); CaP CURE and GM60554 (J. C. R.). P. B. F. is the Michael and Stella Chernow Urological Cancer Research Scientist. P. D. holds the Universal Leaf Professorship in Signaling.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Paul B. Fisher, Department of Pathology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032. Phone: (212) 305-3642; E-mail: pbf1{at}columbia.edu

⁷ The abbreviations used are: mda-7, melanoma differentiation associated gene-7; IL, interleukin; As₂O₃, arsenic trioxide; BA, bongkrekic acid; CsA, cyclosporine A; DCFH-DA, 5,6-carboxy-2',7'-dichlorofluorescein diacetate; DiOC₆(3), 3,3'-dihexyloxacarbocyanine iodide; _m, mitochondrial transmembrane potential; HE, hydroethidine; MPT; mitochondrial permeability transition; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide thiazolyl blue; NAC, N-acetyl-L-cysteine; PBzR, peripheral benzodiazepine receptor; PK11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide); ROS, reactive oxygen species; Tiron, 4,5-dihydroxy-1,3-benzenedisulfonic acid; z-VAD.fmk, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone; Ad.mda-7, adenoviral-mediated delivery of mda-7/IL-24; PTP, permeability transition pore.

⁸ S. Waxman, unpublished observations.

Received 8/22/03. Revised 10/10/03. Accepted 10/17/03.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 

1. Huang F., Adelman J., Jiang H., Goldstein N. I., Fisher P. B. Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells. Oncogene, 18: 3546-3552, 1999.[Medline]
2. Jiang H., Kang D. C., Alexandre D., Fisher P. B. RaSH, a rapid subtraction hybridization approach for identifying and cloning differentially expressed genes. Proc. Natl. Acad. Sci. USA, 97: 12684-12689, 2000.[Abstract/Free Full Text]
3. Jiang H., Lin J. J., Su Z. Z., Goldstein N. I., Fisher P. B. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 11: 2477-2486, 1995.[Medline]
4. Ellerhorst J. A., Prieto V. G., Ekmekcioglu S., Broemeling L., Yekell S., Chada S., Grimm E. A. Loss of MDA-7 expression with progression of melanoma. J. Clin. Oncol., 20: 1069-1074, 2002.[Abstract/Free Full Text]
5. Sauane M., Gopalkrishnan R. V., Sarkar D., Su Z. Z., Lebedeva I. V., Dent P., Pestka S., Fisher P. B. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev., 14: 35-51, 2003.[Medline]
6. Pestka, S., Krause, C. D., Sarkar, D., Walter, M. R., Shi, Y., and Fisher, P. B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol., in press, 2003.
7. Jiang H., Su Z. Z., Lin J. J., Goldstein N. I., Young C. S., Fisher P. B. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. USA, 93: 9160-9165, 1996.[Abstract/Free Full Text]
8. Su Z. Z., Madireddi M. T., Lin J. J., Young C. S., Kitada S., Reed J. C., Goldstein N. I., Fisher P. B. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. USA, 95: 14400-14405, 1998.[Abstract/Free Full Text]
9. Mhashilkar A. M., Schrock R. D., Hindi M., Liao J., Sieger K., Kourouma F., Zou-Yang X. H., Onishi E., Takh O., Vedvick T. S., Fanger G., Stewart L., Watson G. J., Snary D., Fisher P. B., Saeki T., Roth J. A., Ramesh R., Chada S. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol. Med., 7: 271-282, 2001.[Medline]
10. Chada S., Neumanaitis J., Tong A., Zhang Y., Su D., Mhashilkar A., Zhou-Yang H., Parker K., Wilson D., Merritt J., Coffee K. A phase I dose-escalation study of Ad.mda-7 (INGN 241) in patients with advanced carcinoma. Cancer Gene Ther., 8(Suppl.2): S3 2001.
11. Su Z., Lebedeva I. V., Gopalkrishnan R. V., Goldstein N. I., Stein C. A., Reed J. C., Dent P., Fisher P. B. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc. Natl. Acad. Sci. USA, 98: 10332-10337, 2001.[Abstract/Free Full Text]
12. Lebedeva, I. V., Sarkar, D., Su, Z-z., Kitada, S., Dent, P., Stein, C. A., Reed, J., and Fisher, P. B. Bcl-2 and Bcl-x_L differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene, 22: in press, 2003.
13. Bae V. L., Jackson-Cook C. K., Brothman A. R., Maygarden S. J., Ware J. L. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int. J. Cancer, 58: 721-729, 1994.[Medline]
14. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., Susin S. A., Petit P. X., Mignotte B., Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J. Exp. Med., 182: 367-377, 1995.[Abstract/Free Full Text]
15. Castedo M., Ferri K. F., Roumier T., Metievier D., Zamzami N., Kroemer G. Quantification of mitochondrial alterations associated with apoptosis. J. Immunol. Methods, 265: 39-47, 2002.[Medline]
16. Jacobson M. D. Reactive oxygen species and programmed cell death. Trends Biochem. Sci., 21: 83-86, 1996.[Medline]
17. Jing Y., Dai J., Chalmers-Redman R. M., Tatton W. G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 94: 2102-2111, 1999.[Abstract/Free Full Text]
18. Dai J., Weinberg R. S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93: 268-277, 1999.[Abstract/Free Full Text]
19. Kroemer G., Reed J. C. Mitochondrial control of cell death. Nat. Med., 6: 513-519, 2000.[Medline]
20. Zoratti M., Szabo I. The mitochondrial permeability transition. Biochim. Biophys. Acta, 1241: 139-176, 1995.[Medline]
21. Vayssiere J. L., Petit P. X., Risler Y., Mignotte B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc. Natl. Acad. Sci. USA, 91: 11752-11756, 1994.[Abstract/Free Full Text]
22. Crompton M., Ellinger H., Costi A. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem. J., 255: 357-360, 1988.[Medline]
23. Marchetti P., Castedo M., Susin S. A., Zamzami N., Hirsch T., Macho A., Haeffner A., Hirsch F., Geuskens M., Kroemer G. Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med., 184: 1155-1160, 1996.[Abstract/Free Full Text]
24. Klingenberg M., Grebe K., Heldt H. W. On the inhibition of the adenine nucleotide translocation by bongkrekic acid. Biochem. Biophys. Res. Commun., 39: 344-351, 1970.[Medline]
25. Pastorino J. G., Simbula G., Gilfor E., Hoek J. B., Farber J. L. Protoporphyrin IX, an endogenous ligand of the peripheral benzodiazepine receptor, potentiates induction of the mitochondrial permeability transition and the killing of cultured hepatocytes by rotenone. J. Biol. Chem., 269: 31041-31046, 1994.[Abstract/Free Full Text]
26. Pataer A., Chada S., Hunt K. K., Roth J. A., Swisher S. G. Adenoviral melanoma differentiation-associated gene 7 induces apoptosis in lung cancer cells through mitochondrial permeability transition-independent cytochrome c release. J. Thorac. Cardiovasc.Surg., 125: 1328-1335, 2003.[Abstract/Free Full Text]
27. Zamzami N., Susin S. A., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M., Kroemer G. Mitochondrial control of nuclear apoptosis. J. Exp. Med., 183: 1533-1544, 1996.[Abstract/Free Full Text]
28. Marchetti P., Hirsch T., Zamzami N., Castedo M., Decaudin D., Susin S. A., Masse B., Kroemer G. Mitochondrial permeability transition triggers lymphocyte apoptosis. J. Immunol., 157: 4830-4836, 1996.[Abstract]
29. Kane D. J., Sarafian T. A., Anton R., Hahn H., Gralla E. B., Valentine J. S., Ord T., Bredesen D. E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science (Wash. DC), 262: 1274-1277, 1993.[Abstract/Free Full Text]
30. Hockenbery D. M., Oltvai Z. N., Yin X. M., Milliman C. L., Korsmeyer S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241-251, 1993.[Medline]
31. Weil M., Jacobson M. D., Coles H. S., Davies T. J., Gardner R. L., Raff K. D., Raff M. C. Constitutive expression of the machinery for programmed cell death. J. Cell Biol., 133: 1053-1059, 1996.[Abstract/Free Full Text]
32. Vander Heiden M. G., Chandel N. S., Williamson E. K., Schumacker P. T., Thompson C. B. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell, 91: 627-637, 1997.[Medline]
33. Gottlieb E., Vander Heiden M. G., Thompson C. B. Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor -induced apoptosis. Mol. Cell. Biol., 20: 5680-5689, 2000.[Abstract/Free Full Text]
34. Veis D. J., Sorenson C. M., Shutter J. R., Korsmeyer S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell, 75: 229-240, 1993.[Medline]
35. Su Z-z., Lebedeva I. V., Sarkar D., Gopalkrishnan R. V., Sauane M., Sigmon C., Yacoub A., Valerie K., Dent P., Fisher P. B. Melanoma differentiation associated gene-7. mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene, 22: 1164-1180, 2003.[Medline]
36. Fisher P. B., Gopalkrishnan R. V., Chada S., Ramesh R., Grimm E. A., Rosenfeld M. R., Curiel D. T., Dent P. mda-7/IL-24, Novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol. Therapy., 2(Suppl. 1): 24-38, 2003.

This article has been cited by other articles:

				M. Sauane, Z.-z. Su, P. Gupta, I. V. Lebedeva, P. Dent, D. Sarkar, and P. B. Fisher Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis PNAS, July 15, 2008; 105(28): 9763 - 9768. [Abstract] [Full Text] [PDF]

				L. Emdad, I. V. Lebedeva, Z.-Z. Su, D. Sarkar, P. Dent, D. T. Curiel, and P. B. Fisher Melanoma differentiation associated gene-7/interleukin-24 reverses multidrug resistance in human colorectal cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2985 - 2994. [Abstract] [Full Text] [PDF]

				I. V. Lebedeva, I. Washington, D. Sarkar, J. A. Clark, R. L. Fine, P. Dent, D. T. Curiel, N. J. Turro, and P. B. Fisher Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas PNAS, February 27, 2007; 104(9): 3484 - 3489. [Abstract] [Full Text] [PDF]

				B. H. Y. Yeung, D.-C. Huang, and F. A. Sinicrope PS-341 (Bortezomib) Induces Lysosomal Cathepsin B Release and a Caspase-2-dependent Mitochondrial Permeabilization and Apoptosis in Human Pancreatic Cancer Cells J. Biol. Chem., April 28, 2006; 281(17): 11923 - 11932. [Abstract] [Full Text] [PDF]

				I. V. Lebedeva, D. Sarkar, Z.-Z. Su, R. V. Gopalkrishnan, M. Athar, A. Randolph, K. Valerie, P. Dent, and P. B. Fisher Molecular Target-Based Therapy of Pancreatic Cancer Cancer Res., February 15, 2006; 66(4): 2403 - 2413. [Abstract] [Full Text] [PDF]

				Y. Fernandez, T. P. Miller, C. Denoyelle, J. A. Esteban, W.-H. Tang, A. L. Bengston, and M. S. Soengas Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: IMPACT ON TUMOR CELL DEATH J. Biol. Chem., January 13, 2006; 281(2): 1107 - 1118. [Abstract] [Full Text] [PDF]

				P. B. Fisher Is mda-7/IL-24 a "Magic Bullet" for Cancer? Cancer Res., November 15, 2005; 65(22): 10128 - 10138. [Abstract] [Full Text] [PDF]

				D. Sarkar, Z.-z. Su, N. Vozhilla, E. S. Park, P. Gupta, and P. B. Fisher Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice PNAS, September 27, 2005; 102(39): 14034 - 14039. [Abstract] [Full Text] [PDF]

				Y. Jing, N. Hellinger, L. Xia, A. Monks, E. A. Sausville, A. Zelent, and S. Waxman Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells Cancer Res., September 1, 2005; 65(17): 7847 - 7855. [Abstract] [Full Text] [PDF]

				M. Sauane, I. V. Lebedeva, Z.-z. Su, H.-t. Choo, A. Randolph, K. Valerie, P. Dent, R. V. Gopalkrishnan, and P. B. Fisher Melanoma Differentiation Associated Gene-7/Interleukin-24 Promotes Tumor Cell-Specific Apoptosis through Both Secretory and Nonsecretory Pathways Cancer Res., May 1, 2004; 64(9): 2988 - 2993. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebedeva, I. V. Articles by Fisher, P. B. Search for Related Content PubMed PubMed Citation Articles by Lebedeva, I. V. Articles by Fisher, P. B.